About The Study: Among patients with heart failure with mildly reduced ejection fraction/heart failure with preserved ejection fraction in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure randomized clinical trial, higher proportions of cardiovascular and overall mortality in those with ejection fraction less than 50% were related principally to higher proportions of sudden death. A clear treatment effect of finerenone on cardiovascular or cause-specific mortality was not identified, although the trial was likely underpowered for these outcomes.
Corresponding Author: To contact the corresponding author, Akshay S. Desai, MD MPH, email adesai@bwh.harvard.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2025.0860)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the American College of Cardiology’s Annual Scientific Session.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2025.0860?guestAccessKey=f36c1246-8497-426e-8e67-6a1321a10320&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=033025
JAMA Cardiology